Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. (PCVX)
Company Research
Source: GlobeNewswire
FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About VaxcyteVaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, com
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board [Yahoo! Finance]Yahoo! Finance
- Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $95.00 price target on the stock.MarketBeat
- Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst [Seeking Alpha]Seeking Alpha
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
PCVX
Earnings
- 11/6/23 - Miss
PCVX
Sec Filings
- 4/25/24 - Form 4
- 4/23/24 - Form 144
- 4/22/24 - Form 4
- PCVX's page on the SEC website